Restatement of Previously Issued Financial Statements (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Condensed Consolidated Balance Sheet
Warrant liabilities	$ 1,261,550						$ 1,261,550
Total current liabilities	36,769,262						36,769,262		$ 46,164,225
Total liabilities	36,769,262						36,769,262		46,712,052
Additional paid-in capital	161,261,845						161,261,845		46,365,863
Accumulated deficit	(152,835,538)						(152,835,538)		(90,179,720)
Total stockholders' equity (deficit)	8,481,117	$ (39,767,431)	$ 6,390,824	$ (2,828,954)	$ (5,921,867)	$ (6,117,620)	8,481,117	$ (2,828,954)	$ (43,770,883)	$ (4,843,405)
Condensed Consolidated Statement of Operations
Change in fair value of warrant liabilities	16,536,470						(822,539)
Total other (income) expenses	16,950,180			12,513			(164,650)	385,118
Loss before tax	(37,049,331)			(5,161,712)			(62,655,819)	(6,649,481)
Net loss	(37,049,331)	(117,613)	(25,488,874)	(5,161,712)	102,287	(1,590,056)	(62,655,819)	(6,649,481)
Net loss attributable to common stockholders	$ (37,049,331)			$ (5,161,712)			$ (318,477,890)	$ (6,649,481)
Net loss per share:
Basic	$ (0.72)			$ (0.15)			$ (1.45)	$ (0.20)
Diluted	(0.72)			(0.15)			(1.45)	(0.20)
Net loss per share attributable to common stockholders:
Basic	(0.72)			(0.15)			(7.36)	(0.20)
Diluted	$ (0.72)			$ (0.15)			$ (7.36)	$ (0.20)
Condensed Consolidated Statement of Stockholders' Equity (Deficit)
Effect of Merger and recapitalization, net of redemptions and issuance costs		(64,836,244)					$ (64,836,244)
Merger and recapitalization, redemptions and issuance costs		1,412,846					1,412,846
Issuance of common stock for exercise of warrants and Unit Purchase Options	$ 47,319,504						47,319,504
Net income (loss)	(37,049,331)	(117,613)	(25,488,874)	$ (5,161,712)	102,287	(1,590,056)	(62,655,819)	$ (6,649,481)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	(37,049,331)	$ (117,613)	$ (25,488,874)	$ (5,161,712)	$ 102,287	$ (1,590,056)	(62,655,819)	$ (6,649,481)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities							(822,539)
Non-cash investing and financing activities
Reclassification of legacy NeuroRx warrants to warrant liability							38,220,448
Reclassification of warrant liability upon exercise of warrant							38,120,032
As previously reported
Condensed Consolidated Balance Sheet
Warrant liabilities	775,263						775,263
Total current liabilities	36,282,975						36,282,975
Total liabilities	36,282,975						36,282,975
Additional paid-in capital	161,362,260						161,362,260
Accumulated deficit	(152,449,666)						(152,449,666)
Total stockholders' equity (deficit)	8,967,404						8,967,404
Condensed Consolidated Statement of Operations
Change in fair value of warrant liabilities	260,238						(1,208,412)
Total other (income) expenses	673,948						(550,523)
Loss before tax	(20,773,099)						(62,269,946)
Net loss	(20,773,099)						(62,269,946)
Net loss attributable to common stockholders	$ (20,773,099)						$ (318,092,017)
Net loss per share:
Basic	$ (0.40)						$ (1.44)
Diluted	(0.40)						(1.44)
Net loss per share attributable to common stockholders:
Basic	(0.40)						(7.35)
Diluted	$ (0.40)						$ (7.35)
Condensed Consolidated Statement of Stockholders' Equity (Deficit)
Effect of Merger and recapitalization, net of redemptions and issuance costs							$ (26,615,796)
Issuance of common stock for exercise of warrants and Unit Purchase Options							9,199,471
Net income (loss)	$ (20,773,099)						(62,269,946)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	(20,773,099)						(62,269,946)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities							(1,208,412)
Adjustment
Condensed Consolidated Balance Sheet
Warrant liabilities	486,287						486,287
Total current liabilities	486,287						486,287
Total liabilities	486,287						486,287
Additional paid-in capital	(100,415)						(100,415)
Accumulated deficit	(385,872)						(385,872)
Total stockholders' equity (deficit)	(486,287)						(486,287)
Condensed Consolidated Statement of Operations
Change in fair value of warrant liabilities	16,276,232						385,873
Total other (income) expenses	16,276,232						385,873
Loss before tax	(16,276,232)						(385,873)
Net loss	(16,276,232)						(385,873)
Net loss attributable to common stockholders	$ (16,276,232)						$ (385,873)
Net loss per share:
Basic	$ (0.32)						$ (0.01)
Diluted	(0.32)						(0.01)
Net loss per share attributable to common stockholders:
Basic	(0.32)						(0.01)
Diluted	$ (0.32)						$ (0.01)
Condensed Consolidated Statement of Stockholders' Equity (Deficit)
Effect of Merger and recapitalization, net of redemptions and issuance costs							$ (38,220,448)
Issuance of common stock for exercise of warrants and Unit Purchase Options							38,120,033
Net income (loss)	$ (16,276,232)						(385,873)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (16,276,232)						(385,873)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities							385,873
Non-cash investing and financing activities
Reclassification of legacy NeuroRx warrants to warrant liability							38,220,448
Reclassification of warrant liability upon exercise of warrant							$ 38,120,032